Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
Aspirin; Caffeine
GlaxoSmithKline Consumer Healthcare (Ireland) Limited
N02BA; N02BA51
Aspirin; Caffeine
325/15 milligram(s)
Film-coated tablet
Salicylic acid and derivatives; acetylsalicylic acid, combinations excl. psycholeptics
Marketed
1983-01-10
28.3401 202427 Interleaved 2 of 5 Barcode Type Barcode Number: Magnification: BARCODE INFO BWR: 0 Micrometre 70% 50% 1. 20% BLACK Aprilia Ireland ANADIN ORIGINAL WYA0062 - SC: 0032 Offset N/A 62000000202427 N/A Leaflet N/A N/A N/A TR2755442/A 0000015152 AIP_CHAMPS_2022_HALEON_Version 1 07 - Feb - 2023 V1 STUDIO LOCATION: NON PRODUCTION D2A AWP NO: Artwork Information Panel CHAMPS NO: MANUFACTURING SITE: SITE COMPONENT NO: SITE CHANGE CONTROL NO: APPROVING MARKET: PRODUCT MARKET TRADE NAME: MATERIAL SPEC NO: PRINT PROCESS: TECHNICAL DRAWING NO: BARCODE NO: BAR WIDTH REDUCTION: PHARMA CODE NO: TOTAL NUMBER OF COLOURS INCLUDING VARNISH & FOILS: TOTAL SPECIAL FINISHES: X No MICRO TEXT: 6.0pt 5.5pt 6.3pt 94% BODY TEXT SIZE: N/A FORMULATION CODE SMALLEST TEXT SIZE: LEADING: HORIZONTAL SCALE: PRODUCTION COMPONENT TYPE: 0 1 EUROPE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in the leaflet or as your doctor or pharmacist told you. Keep this leaflet. You may need to read it again. Ask your pharmacist if you need more information or advice. IF YOU GET ANY SIDE EFFECTS, TALK TO YOUR DOCTOR, PHARMACIST OR NURSE. THIS INCLUDES ANY POSSIBLE SIDE EFFECTS NOT LISTED IN THIS LEAFLET. SEE SECTION 4. YOU MUST SEE A DOCTOR IF YOUR SYMPTOMS WORSEN OR DO NOT IMPROVE AFTER 3 DAYS. IN THIS LEAFLET: 1. What your medicine is and what it is used for 2. What you need to know before you take your medicine 3. How to take your medicine 4. Possible side effects 5. How to store your medicine 6. Contents of the pack and other information 1. WHAT YOUR MEDICINE IS AND WHAT IT IS USED FOR Each Film-coated tablet contains 325 mg of Aspirin (Acetylsalicylic Acid), and 15 mg of Caffeine. Aspirin belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). These products relieve pain and inflammation and reduce fever. In addition, your medicine contains caffeine, which increases the pain-relieving effect Läs hela dokumentet
Health Products Regulatory Authority 15 May 2023 CRN00DKCP Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Anadin Analgesic Film-coated Tablets Aspirin 325mg Caffeine 15mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Acetylsalicylic acid (aspirin) 325.0 mg Caffeine 15.0 mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM White capsule shaped, film coated tablets. The tablets have '325/15' engraved on both sides. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the relief of pain of headache, neuralgia, rheumatic pain, period pain, dental pain, toothache, and the relief of symptoms of the common cold. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Oral ADULTS AND ADOLESCENTS OVER 16 YEARS: Take 2 tablets every 4 hours if necessary. Do not exceed 12 tablets in any 24 hour period. Do not give to children and adolescents aged under 16 years, except on medical advice, where the benefit outweighs the risk. ELDERLY: Non-steroidal anti-inflammatory drugs should be used with particular caution in elderly patients who are more prone to adverse events. The lowest dose compatible with adequate safe clinical control should be employed. See also Section 4.4. 4.3 CONTRAINDICATIONS Patients with a history of hypersensitivity reactions (e.g. bronchospasm, rhinitis, urticaria) in response to Anadin Analgesic Film-coated Tablets, aspirin or other non-steroidal anti-inflammatory drugs or any of the other constituents. Children and adolescents under 16 years. Breast-feeding. Last-trimester of pregnancy. Concurrent anti-coagulant therapy. Patients with severe renal failure. Intake of more than 15mg methotrexate per week. Health Products Regulatory Authority 15 May 2023 CRN00DKCP Page 2 of 8 History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). Use in patients with severe heart failure. Use in patients with bl Läs hela dokumentet